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Abstract
The xenoestrogenic mycotoxin zearalenone is a Fusarium-derived food and feed contaminant. In mammals, the reduced (e.g.,
zearalanone, α-zearalanol, and β-zearalanol) and conjugated (e.g., zearalenone-14-sulfate) metabolites of zearalenone are
formed. Furthermore, filamentous fungi and plants are also able to convert zearalenone to conjugated derivatives, including
zearalenone-14-sulfate and zearalenone-14-glucoside, respectively. Serum albumin is the dominant plasma protein in the circu-
lation; it interacts with certain mycotoxins, affecting their toxicokinetics. In a previous investigation, we demonstrated the
remarkable species differences regarding the albumin binding of zearalenone and zearalenols. In the current study, the interac-
tions of zearalanone, α-zearalanol, β-zearalanol, zearalenone-14-sulfate, and zearalenone-14-glucoside with human, bovine,
porcine, and rat serum albumins were examined, employing fluorescence spectroscopy and affinity chromatography.
Zearalanone, zearalanols, and zearalenone-14-sulfate form stable complexes with albumins tested (K = 9.3 × 103 to 8.5 × 105
L/mol), while the albumin binding of zearalenone-14-glucoside seems to be weak. Zearalenone-14-sulfate formed themost stable
complexes with albumins examined. Considerable species differences were observed in the albumin binding of zearalenone
metabolites, which may have a role in the interspecies differences regarding the toxicity of zearalenone.
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Introduction
Zearalenone (ZEN) is a xenoestrogenic mycotoxin produced
by Fusarium species. It appears as a contaminant in crops,
cereal-based products (e.g., flour, bakery goods, and beer),
and in other commodities (Rogowska et al. 2019). Despite
its nonsteroidal structure, ZEN can bind to estrogen receptors
(Loi et al. 2017; Shier et al. 2001) causing reproductive dis-
orders, as well as its potential genotoxic, hepatotoxic, terato-
genic, and immunotoxic effects are also suggested (Rai et al.
2019; Rogowska et al. 2019). The involvement of ZEN in the
development of breast and esophageal cancers has been
emerged; however, ZEN is classified as a group 3 carcinogen
by the IARC (Rai et al. 2019).
ZEN is extensively biotransformed in mammals (Rai et al.
2019). Its reduction by hydroxysteroid dehydrogenases leads to
the formation of α- and β-zearalenols (α- and β-ZELs),
zearalanone (ZAN, Fig. 1), and α- and β-zearalanols (α- and
β-ZALs, Fig. 1) (EFSA 2017). Some of these metabolites (e.g.,
α-ZEL and α-ZAL) show considerably higher xenoestrogenic
effects than ZEN (EFSA 2017; Fleck et al. 2017; Frizzell et al.
2011; Filannino et al. 2011). Furthermore, α-ZAL (also known
as zeranol) is administered as a growth promoter to farm ani-
mals, leading to the appearance of the residual α-ZAL in food,
mainly in beef (Mukherjee et al. 2014; EFSA 2017). Therefore,
this application of α-ZAL is prohibited in the EU (while it is
still available in some countries/regions, such as North
America, Chile, Australia, New Zealand, South Africa, and
Japan) (Mukherjee et al. 2014). In addition, the exposure to
ZEN and α-ZAL may be responsible for the more frequent
development of precocious puberty among young girls
(Mukherjee et al. 2014).
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As a result of the phase II metabolism of ZEN, the glucu-
ronic acid and sulfate conjugates of ZEN, ZELs, and ZALs are
produced, such as zearalenone-14-glucuronide and
zearalenone-14-sulfate (Z14S; also known as zearalenone-4-
sulfate; Fig. 1) (Mirocha et al. 1981; Olsen et al. 1986;
Dänicke and Winkler 2015; EFSA 2017; Warth et al. 2019).
In mammals, glucuronide conjugates take part in
enterohepatic circulation, during which they are cleaved in
the intestines, and the reabsorption of the deconjugated prod-
ucts considerably increases their elimination half-life
(Dänicke et al. 2005; EFSA 2017).
Plants and filamentous fungi can also modify the structures
of parent mycotoxins (Berthiller et al. 2013). Mycotoxin de-
rivatives formed during these reactions, and via other biolog-
ical or chemical degradation processes, are classified as mod-
ified mycotoxins (Rychlik et al. 2014; Freire and Sant’Ana
2018). Among modified mycotoxins, the plant-produced con-
jugates are called masked mycotoxins (Rychlik et al. 2014).
Plants and/or filamentous fungi can convert ZEN to Z14S
(molar ratios of ZEN to Z14S are between 12:1 and 2:1);
therefore, the latter compound appears as a food contaminant
(Freire and Sant’Ana 2018; Plasencia and Mirocha 1991;
Berthiller et al. 2006). The amount of Z14S in cereal-based
products showed high variations (1–417 μg/kg), depending
on the product tested and the year of harvest (Vendl et al.
2010; De Boevre et al. 2012). Zearalenone-14-glucoside
(Z14G; also known as zearalenone-4-glucoside; Fig. 1) is an
abundant plant-produced conjugate of ZEN, which has been
found in ZEN-contaminated grain-based products (Berthiller
et al. 2013; Vendl et al. 2010). Typically, in vitro models
demonstrate the lower toxicity of ZEN conjugates compared
with the parent mycotoxin. Previous in vitro studies described
that the glucoside conjugation of ZEN prevents the binding of
these derivatives to the human estrogen receptors
(Poppenberger et al. 2006), and the significantly lower (100-
fold) estrogenicity of Z14S vs. ZEN has been also reported
(Drzymala et al. 2015). However, the gut microbiota can hy-
drolyze these metabolites, leading to the formation of ZEN
(Berthiller et al. 2013; EFSA 2017). After the oral administra-
tion of Z14S and Z14G to pigs, their complete intestinal hy-
drolysis to ZEN was observed (Binder et al. 2017). Therefore,
the EFSA evaluation suggests that the risks regarding the ex-
posure to Z14S and Z14G should be considered similar to
ZEN (EFSA 2017). The European Food Safety Authority
(EFSA) CONTAM Panel established human tolerable daily
intake (TDI) of 0.25 μg/kg body weight per day, denoted as
ZEN equivalents for ZEN and its modified forms jointly
(EFSA 2014).
Serum albumin is the major protein in the circulation; it
binds to several endogenous compounds and xenobiotics.
The complex formation can affect the tissue distribution and
the elimination half-life of ligand molecules (Fanali et al.
2012; Yamasaki et al. 2013). ZEN and ZELs form stable
complexes with serum albumin, showing considerable species
differences (Poór et al. 2017; Ma et al. 2018; Faisal et al.
2018). For example, the affinity of ZEN and ZELs towards
rat albumin is approximately tenfold higher compared with
albumins from other species (Faisal et al. 2018). The differ-
ences in albumin binding may be partly responsible for the
high variations in the toxicokinetics of ZEN and its deriva-
tives, and may help to understand the vulnerability of some
species vs. these mycotoxins. Cirlini et al. reported the absorp-
tion and partial deglycosylation of Z14G in an in vitro model
with CaCo-2 cells, the absorption of Z14G was considerably
Fig. 1 Chemical structures of zearalanone (ZAN), α-zearalanol (α-ZAL), β-zearalanol (β-ZAL), zearalenone-14-sulfate (Z14S), and zearalenone-14-
glucoside (Z14G)
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lower compared with ZEN (Cirlini et al. 2016). After the oral
administration of Z14G to rats, its low plasma concentrations
were detected (Sun et al. 2019). Furthermore, approximately
61% of the orally administered Z14G was absorbed in pigs,
which was followed by the significant presystemic hydrolysis
of the masked mycotoxin (Catteuw et al. 2019). These data
indicate that a lower fraction of Z14G can reach the systemic
circulation. A previous study suggests the interaction of Z14G
with human serum albumin (HSA), during which albumin can
slowly hydrolyze the masked mycotoxin to ZEN (Dellafiora
et al. 2017).
In this study, the interactions of ZAN, α-ZAL, β-ZAL,
Z14S, and Z14G with human (HSA), bovine (BSA), porcine
(PSA), and rat (RSA) serum albumins were investigated by
fluorescence spectroscopy. Furthermore, to confirm the re-
sults of spectroscopic studies, the interactions of ZEN metab-
olites with HSA were also examined with high-performance
affinity chromatography (HPAC).
Materials and methods
Reagents
Zearalenone (ZEN; MW = 318.36 g/mol; purity: 99.7%,
HPLC), zearalanone (ZAN; MW = 320.38 g/mol; purity:
100%, TLC ), α-zearalanol (α-ZAL; MW = 322.40 g/mol;
purity: 98%, HPLC), β-zearalanol (β-ZAL; MW = 322.40
g/mol; purity: 98%, HPLC), HSA (MW = 66.4 kDa), BSA
(MW = 66.4 kDa), PSA (MW = 67.5 kDa), RSA (MW = 64.6
kDa), and warfarin (MW = 308.3 g/mol) were obtained from
Sigma-Aldrich (Saint Louis, MO, USA). Zearalenone-14-
sulfate ammonium salt (Z14S; MW = 415.46 g/mol; purity:
98.5%, HPLC, NMR, LC-MS) was purchased from ASCA
GmbH (Berlin, Germany). Zearalenone-14-O-β-D-glucoside
(Z14G; MW = 480.50 g/mol; purity: 99.4%, HPLC, NMR)
was obtained from Honeywell (Charlotte, NC, USA). Stock
solutions of mycotoxins (5000 μmol/L; ZEN: 1.592 g/L;
ZAN: 1.602 g/L; ZALs: 1.612 g/L; Z14S ammonium salt:
2.078 g/L; and Z14G: 2.403 g/L) were prepared in ethanol
(96 v/v%, spectroscopic grade; VWR, Debrecen, Hungary)
and stored at – 20 °C.
Spectroscopy
Fluorescence spectroscopic measurements were carried out
employing a Hitachi F-4500 fluorescence spectrophotometer
(Hitachi, Tokyo, Japan) to investigate the effect of increasing
mycotoxin concentrations on the fluorescence signal of albu-
mins as well as on the emission spectrum of warfarin-HSA
complex. Our studies were executed in phosphate-buffered
saline (PBS, pH 7.4; 8.00 g/L NaCl, 0.20 g/L KCl, 1.81 g/L
Na2HPO4 × 2H2O, 0.24 g/L KH2PO4) at room temperature, in
the presence of air.
For spectral correction of fluorescence emission intensities,
absorption spectra of mycotoxins were also recorded applying
a Jasco-V730 spectrophotometer (Jasco, Tokyo, Japan). The
inner-filter effect of mycotoxins was corrected as described
previously (Hu and Liu 2015; Faisal et al. 2018):
I cor ¼ Iobs  e AexþAemð Þ=2 ð1Þ
where Icor and Iobs indicate the corrected and observed fluo-
rescence emission intensities, respectively. Aex and Aem de-
note the absorbance of mycotoxins at the excitation and emis-
sion wavelengths used, respectively.
To investigate the stability of mycotoxin-albumin com-
plexes, mycotoxin-induced quenching effects on the intrinsic
fluorescence of albumins were tested. The emission signal of
albumins (2 μmol/L; λex = 295 nm; λex = 340 nm) were
measured in the presence of increasing concentrations of my-
cotoxins (0.0, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, and 10.0
μmol/L). Stern-Volmer quenching constants (KSV; unit:
L/mol) were determined employing the Stern-Volmer equa-
tion (Ma et al. 2018; Faisal et al. 2018):
I0
I
¼ 1þ KSV  Q½  ð2Þ
where Q is the concentration of the mycotoxin (unit: mol/L).
I0 and I are the fluorescence emission signal of albumin in the
absence and presence of mycotoxins, respectively. Z14S and
Z14G exert fluorescence; their excitation and emission spec-
tra, under different environmental conditions, have been re-
ported previously (Faisal et al. 2019, 2020). Under the applied
circumstances, the emission signals of Z14S and Z14G did not
interfere with the evaluation of fluorescence studies (e.g., the
emission maxima of albumins and warfarin-HSA complex).
Furthermore, ZAN and ZALs did not exert fluorescence at the
concentrations applied.
Binding constants (K; unit: L/mol) of mycotoxin-albumin
complexes were determined by nonlinear fitting employing
Hyperquad2006 software, as described in details in our previ-
ous studies (Sueck et al. 2018; Faisal et al. 2018).
To test the effects of ZEN metabolites on warfarin-HSA
interaction, our previously reported method was applied
(Faisal et al. 2018; Fliszár-Nyúl et al. 2019). In this experi-
ment, the fluorescence emission signal of warfarin (1 μmol/L;
λex = 317 nm, λem = 379 nm) was examined in the presence of
HSA (3.5 μmol/L) without and with mycotoxins (0, 1, 2, 3, 4,
5, 6, 8, 10, and 15 μmol/L) in PBS (pH 7.4). Under these
conditions, approximately 70% of warfarin is albumin-bound.
Since albumin-bound warfarin shows much higher fluores-
cence than the free fluorophore (Faisal et al. 2018), the chang-
es in its fluorescence can indicate the increased or decreased
albumin binding of warfarin.
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High-performance affinity chromatography
HPAC was performed with a HSA-coated column (Faisal
et al. 2018). The HPLC system (Jasco, Tokyo, Japan) used
for the analysis included an autosampler (AS-4050), a binary
pump (PU-4180), and a diode-array detector (MD-4017). A
5-μL volume of samples (ZAN: 200 μmol/L; ZEN, α-ZAL,
β-ZAL, and Z14S: 100 μmol/L; Z14G: 50 μmol/L) was driv-
en through a pre-column filter (Waters, Milford, MA, USA)
linked to an immobilized HSA-coated HPAC column
(Chiralpak® HSA, 50 × 3.0 mm, 5 μm; Daicel, Tokyo,
Japan). The isocratic elution was performed with 0.5-mL/
min flow rate at room temperature. The mobile phase
contained isopropanol (HPLC grade; VWR, Debrecen,
Hungary) and 0.01 mol/L pH 7.0 ammonium acetate buffer
(15:85 v/v%). Mycotoxins were detected at 235 nm, and chro-
matograms were evaluated with ChromNAV software.
Results and discussion
Fluorescence quenching studies
In this experiment, the fluorescence quenching effects of
ZAN, ZALs, Z14S, and Z14G (0-10 μmol/L each) on albu-
mins (2 μmol/L) were investigated in PBS, using 295 nm
excitation wavelength. Under these circumstances, albumins
showed their emission wavelength maxima around 340 nm.
Inner-filter effects of ZEN metabolites were eliminated
employing Eq. 1. Z14G did not affect the emission signals
of albumins (data not shown); therefore, it is reasonable to
hypothesize that Z14G does not interact or forms only low-
affinity complexes with albumins. However, other myco-
toxins tested induced concentration-dependent decrease in
the fluorescence of albumins at 340 nm (Fig. 2), suggesting
the formation of albumin-ligand complexes (Tan et al. 2019;
Ma et al. 2018; Faisal et al. 2018; Fliszár-Nyúl et al. 2019).
The strongest quenching effect was shown by Z14S, and an
increasing second peak appeared in these spectra at approxi-
mately 460 nm (Fig. 2d), which is the fluorescence signal of
Z14S. Despite the fact that ZEN and ZELs exert intrinsic
fluorescence (Faisal et al. 2018), ZAN and ZALs showed
negligible fluorescence under the applied conditions.
Therefore, no secondary peaks appeared in Fig. 2a–c.
Based on the mycotoxin-induced quenching effects, Stern-
Volmer quenching constants (KSV, unit: L/mol; Table 1) and
binding constants (K, unit: L/mol; Table 2) of albumin-ligand
complexes were determined employing the graphical applica-
tion of the Stern-Volmer equation (Eq. 2) and the
Hyperquad2006 software, respectively. Stern-Volmer plots
are demonstrated in Fig. 3, displaying good linearity for inter-
actions tested (R2 = 0.97–0.99). Hyperquad evaluation
showed the best fitting with the 1:1 stoichiometry of complex
formation; furthermore, good correlation of KSV and K values
was observed (see in Tables 1 and 2). ZEN metabolites tested
(except Z14G) formed stable complexes with albumins, show-
ing K values in a wide range (104 to 106 L/mol). Similarly to
ZEN and ZELs (Faisal et al. 2018), mycotoxins formed the
most stable complexes with RSA (Table 2). ZAN and ZALs
bound with the lowest affinity to PSA or BSA, while Z14S
formed the least stable complex with HSA among albumins
tested. Furthermore, Z14S bound to each albumin with higher
affinity than ZAN and ZALs, showing considerably stronger
interactions with BSA and PSA compared with the reduced
metabolites examined in this study. The binding constants of
ZAN and ZALs showed minor differences regarding one in-
dividual albumin (Table 2). Typically, ZAN and ZALs formed
less stable complexes with albumins than the parent com-
pound ZEN; in contrast, Z14S-albumin displayed higher sta-
bility vs. ZEN-albumin complexes, except HSA (Faisal et al.
2018). Remarkable species-dependent differences were no-
ticed regarding the albumin binding of ZAN, ZALs, and
Z14S. For example, the binding affinity of ZAN-RSA vs.
ZAN-PSA (14-fold), α-ZAL-RSA vs. α-ZAL-BSA (9-fold),
β-ZAL-RSA vs. β-ZAL-BSA (30-fold), and Z14S-RSA and
Z14S-HSA (16-fold) showed major differences (Table 2).
Similarly, high species-dependent differences in albumin
binding have been also reported regarding ZEN, ZELs, and
ochratoxin A (Faisal et al. 2018; Hagelberg et al. 1989; Poór
et al. 2014).
The toxicokinetics of ZEN show large variances in differ-
ent species, which may be partly resulted from the species-
dependent alternations in albumin binding of ZEN and its
metabolites (Fruhauf et al. 2019). Some of the recent in vivo
studies support this hypothesis (Fruhauf et al. 2019; Catteuw
et al. 2019; Mukherjee et al. 2014). In pigs, the lower affinity
of the mycotoxin towards PSA (Z14G < β-ZEL < α-ZEL <
ZEN) was accompanied with its earlier disappearance from
the circulation (Catteuw et al. 2019; Faisal et al. 2018), which
propose the potential impact of albumin binding on the
toxicokinetics of these mycotoxins. Furthermore, the signifi-
cantly longer plasma elimination half-lives of ZEN and α-
ZAL have been reported in rats vs. in humans (Mukherjee
et al. 2014), which is in agreement with the considerably
higher affinity of ZEN (Faisal et al. 2018) and α-ZAL
(Table 2) towards RSA compared to HSA.
Elution of ZEN and its metabolites from HSA-HPAC
column
To confirm the results of quenching studies, the interactions of
ZEN, ZAN, ZALs, Z14S, and Z14G with HSA were also
examined employing HPAC. The stronger interaction of the
ligand molecule with HSA leads to its longer elution from the
HSA-HPAC column. The mycotoxins tested were eluted with
the following retention times (tR) from the affinity column
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(Fig. 4): Z14G (1.7 min), β-ZAL (3.1 min), α-ZAL (5.3 min),
ZAN (8.0 min), ZEN (12.3 min), and Z14S (23.3 min). The tR
of Z14G was very short but it was not eluted with the solvent
front, indicating the weak interaction of Z14G with HSA. The
formation of low-affinity Z14G-HSA complexes is in
agreement with the previously reported very slow hydrolysis
of Z14G by the protein (Dellafiora et al. 2017). The tR of ZEN
metabolites (Fig. 4) suggests the same orders in complex sta-
bility than quenching studies (Table 2): Z14S > ZAN > α-
ZAL >β-ZAL > Z14G. Furthermore, the longer tR of ZEN vs.
Fig. 2 Fluorescence quenching
effects of ZEN metabolites on
HSA. Emission spectra of HSA (2
μmol/L) in the presence of
increasing concentrations of
ZAN, α-ZAL, β-ZAL, and Z14S
in PBS (pH 7.4; λex = 295 nm).
Z14G did not affect the emission
spectra of albumins (ZAN
zearalanone, α-ZAL α-
zearalanol, β-ZAL β-zearalanol,
Z14S zearalenone-14-sulfate,
Z14G zearalenone-14-glucoside)
Table 1 Decimal logarithmic values of the Stern-Volmer quenching
constants (KSV; unit: L/mol) of mycotoxin-albumin complexes
Mycotoxin* logKSV ± SEM
HSA BSA PSA RSA
ZEN 5.09 ± 0.01a 4.81 ± 0.01a 4.56 ± 0.02a 5.50 ± 0.01a
ZAN 4.52 ± 0.04 4.41 ± 0.04 3.97 ± 0.06 5.00 ± 0.03
α-ZAL 4.50 ± 0.02 4.20 ± 0.05 4.30 ± 0.05 5.21 ± 0.00
β-ZAL 4.34 ± 0.04 3.88 ± 0.06 4.13 ± 0.09 5.43 ± 0.01
Z14S 4.64 ± 0.03 5.32 ± 0.02 5.04 ± 0.02 5.70 ± 0.02
Z14G - - - -
*ZEN zearalenone, ZAN zearalanone, α-ZAL α-zearalanol, β-ZAL β-
zearalanol, Z14S zearalenone-14-sulfate, Z14G zearalenone-14-gluco-
side, HSA human serum albumin, BSA bovine serum albumin, PSA por-
cine serum albumin, RSA rat serum albumin
a Based on Faisal et al. (2018)
Table 2 Decimal logarithmic values of binding constants (K; unit:
L/mol) of mycotoxin-albumin complexes
Mycotoxin* logK ± SEM
HSA BSA PSA RSA
ZEN 5.09 ± 0.01a 4.78 ± 0.01a 4.57 ± 0.01a 5.42 ± 0.00a
ZAN 4.58 ± 0.00 4.51 ± 0.00 3.97 ± 0.01 5.12 ± 0.00
α-ZAL 4.55 ± 0.00 4.34 ± 0.00 4.38 ± 0.00 5.31 ± 0.01
β-ZAL 4.37 ± 0.01 4.12 ± 0.01 4.15 ± 0.01 5.61 ± 0.01
Z14S 4.71 ± 0.03 5.43 ± 0.02 5.12 ± 0.02 5.93 ± 0.02
Z14G - - - -
*ZEN zearalenone, ZAN zearalanone, α-ZAL α-zearalanol, β-ZAL β-
zearalanol, Z14S zearalenone-14-sulfate, Z14G zearalenone-14-gluco-
side, HSA human serum albumin, BSA bovine serum albumin, PSA por-
cine serum albumin, RSA rat serum albumin
a Based on Faisal et al. (2018)
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ZAN, ZALs, and Z14G are also in agreement with the current
results (Table 2) and previous observations (Faisal et al.
2018). However, the tR of Z14S was even longer compared
with ZEN, despite its binding affinity is lower (logKZ14S-HSA
= 4.7; logKZEN-HSA = 5.1) based on quenching studies (Faisal
et al. 2018). This discrepancy may be explained by the differ-
ent experimental conditions in quenching and HPAC studies,
which can influence the stability of albumin-ligand complexes
(Kaspchak et al. 2018). In quenching studies, PBS (pH 7.4)
was applied to mimic extracellular physiological condition.
Fig. 3 Stern-Volmer plots (R2 =
0.969–0.997) of mycotoxin-
albumin interactions: HSA (a),
BSA (b), PSA (c), and RSA (d)
(λex = 295 nm, λem = 340 nm;
ZAN zearalanone, α-ZAL α-
zearalanol, β-ZAL β-zearalanol,
Z14S zearalenone-14-sulfate,
HSA human serum albumin, BSA
bovine serum albumin, PSA por-
cine serum albumin, RSA rat se-
rum albumin)
Fig. 4 HPAC chromatograms of
ZEN, ZAN, α-ZAL, β-ZAL,
Z14S, and Z14G eluted from the
HSA-coated column (see details
in “High-performance affinity
chromatography” section; ZAN
zearalanone, α-ZAL α-
zearalanol, β-ZAL β-zearalanol,
Z14S zearalenone-14-sulfate,
Z14G zearalenone-14-glucoside)
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However, in the HPAC studies, we created appropriate con-
ditions for the affinity column (based on the manufacturer’s
guide); therefore, the buffer was different, the ionic strength
and the pH were lower than in quenching studies, and the
eluent contained isopropanol (see details in the “Materials
and methods” section).
Effects of ZEN metabolites on warfarin-HSA
interaction
In previous studies, the allosteric interactions of ZEN and ZELs
with the Sudlow’s site I ligand warfarin have been reported
(Poór et al. 2017; Faisal et al. 2018): Since the binding sites
of ZEN and ZELs are relatively close to the site I region, these
mycotoxins can increase (ZEN and α-ZEL) or decrease (β-
ZEL) the binding affinity of warfarin towards HSA.
Therefore, the effects of ZAN, ZALs, Z14S, and Z14G on
warfarin-HSA interaction were also examined. Because
albumin-bound warfarin exerts considerably higher fluores-
cence signal at 379 nm than free warfarin, the increase or de-
crease in the fluorescence at 379 nm indicate its elevated or
reduced albumin binding, respectively (Faisal et al. 2018;
Fliszár-Nyúl et al. 2019). Importantly, the inner-filter effects
of mycotoxins were also corrected in these experiments (see
Eq. 1). As Fig. 5 demonstrates, ZAN and α-ZAL considerably
increased the emission signal of warfarin, similar to ZEN and
α-ZEL in our previous study (Faisal et al. 2018). These obser-
vations suggest that ZAN and α-ZAL can increase the binding
affinity of warfarin towards HSA. However, β-ZAL, Z14S,
and Z14G did not affect the fluorescence at 379 nm. Because
Z14G forms low-affinity complexes with HSA, it is not sur-
prising that it did not modify the albumin binding of warfarin.
In our previous study,β-ZEL showed different effect compared
with ZEN and α-ZEL, likely due to its different binding posi-
tion or binding site (Faisal et al. 2018). Therefore, the observa-
tion that β-ZAL and Z14S have no effect on warfarin-HSA
interaction (despite their binding affinities are similar to ZAN
and α-ZAL) suggests their different binding positions/sites
compared with ZEN, ZAN, α-ZEL, and α-ZAL.
In conclusion, fluorescence spectroscopic and HPAC ex-
periments suggest the weak interaction of Z14G with HSA;
however, ZAN, ZALs, and Z14S form stable complexes with
serum albumins investigated (K = 104 to 106 L/mol). In addi-
tion, significant species-dependent differences were observed
in the affinity of ZAN, ZALs, and Z14S towards albumins
from various species (human, bovine, porcine, and rat).
These results suggest that albumin binding may be partly re-
sponsible for the species-dependent alterations in the
toxicokinetics and toxic effects of ZEN and its metabolites
previously described in mammals. For example, the formation
of highly stable complexes of ZEN and α-ZAL with RSA can
explain the long elimination half-lives of these mycotoxins in
rat (Mukherjee et al. 2014). Furthermore, the binding con-
stants determined in the current (Table 1) and previous
(Faisal et al. 2018) studies show good correlation with the
recently reported in vivo experiments performed in pigs
(Catteuw et al. 2019): the higher binding constant causes the
longer lifetime of the mycotoxin in the circulation. These ob-
servations underline the potential toxicokinetic importance of
the albumin-ligand interactions of ZEN and its metabolites.
Based on our data, it is reasonable to hypothesize that the
albumin-bound fraction of ZEN derivatives is significant in
the circulation; therefore, the appropriate sample preparation
is highly important during the analyses of blood samples. In
addition, the formation of stable mycotoxin-albumin com-
plexes likely makes possible the application of albumin as
an affinity protein for the extraction of ZEN and its metabo-
lites, as it has been reported during the extraction of ochratox-
in A with BSA from wine (Leal et al. 2019). Thus, these
interactions may also have some analytical importance.
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Fig. 5 Allosteric effects of ZEN analogs on the binding of warfarin to
HSA. Fluorescence emission signal of warfarin (1 μmol/L) with HSA
(3.5 μmol/L) in the presence of increasing mycotoxin concentrations in
PBS (pH 7.4; λex = 317 nm, λem = 379 nm; ZAN zearalanone, α-ZAL α-
zearalanol, β-ZAL β-zearalanol, Z14S zearalenone-14-sulfate, Z14G
zearalenone-14-glucoside; the inner-filter effects of mycotoxins were
corrected based on Eq. 1)
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